Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous Trappsol Cyclo versus placebo with standard care in Niemann-Pick disease type C1
MOH_2021-10-21_009989Phase 3Recruiting
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Oct 2021
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Trappsol Cyclo in Niemann-Pick disease type C1 (NPC1) (3 arms), sponsored by Cyclo Therapeutics, Inc. Primary endpoint: Change in composite Niemann-Pick disease severity score. Started Oct 2021; status: recruiting.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on MOH_2021-10-21_009989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-21_009989.